Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

Dai, Xinghang; Ren, Long Fang; Liu, Mengxi; Cai, Hao; Zhang, Hu; Gong, Qiyong; Gu, Zhongwei; Luo, Kui

doi:10.1016/j.nantod.2021.101163

Cited by 20 publications

(14 citation statements)

References 213 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through these “CAPIR” principles, elegantly constructed NDDSs can effectively and successfully deliver therapeutic drugs to induce ICD in the tumor site, which is a critical step to activate cancer‐immunity cycle. [ 76 ] Meanwhile, immunotherapeutic agents may modulate immunosuppressive cells including regulatory T cells (Tregs), myeloid‐derived suppressor cells (MDSCs), M2 macrophages [ 77 ] and down‐regulate the expression of immunosuppressive molecules such as indoleamine 2,3‐dioxygenase (IDO) to potentiate immunotherapies. [ 78 ] This is a promising strategy to eradicate neoplasms and inhibit metastasis via acting as vaccination.…”

Section: Design Of Nddss To Deliver Icd‐based Therapeutic Agentsmentioning

confidence: 99%

“…ICD could promote DCs maturation and increase tumor‐infiltrating lymphoid and myeloid cells, [ 101 ] which create an immunoresponsive tumor microenvironment. [ 77 ] By displaying a high degree of T cells infiltration, hot tumors become a fertile ground for effective ICIs‐based therapies. [ 102 ] It has been demonstrated that a hot tumor microenvironment with infiltrated CTLs can significantly increase the response rate to anti‐PD‐1/PD‐L1 antibodies.…”

Section: Icd Induced By Nddss In Combination With Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

et al. 2022

Self Cite

View full text Add to dashboard Cite

Tumor immunotherapy is only effective in a fraction of patients due to a low response rate and severe side effects, and these challenges of immunotherapy in clinics can be addressed through induction of immunogenic cell death (ICD). ICD is elicited from many antitumor therapies to release danger associated molecular patterns (DAMPs) and tumor‐associated antigens to facilitate maturation of dendritic cells (DCs) and infiltration of cytotoxic T lymphocytes (CTLs). The process can reverse the tumor immunosuppressive microenvironment to improve the sensitivity of immunotherapy. Nanostructure‐based drug delivery systems (NDDSs) are explored to induce ICD by incorporating therapeutic molecules for chemotherapy, photosensitizers (PSs) for photodynamic therapy (PDT), photothermal conversion agents for photothermal therapy (PTT), and radiosensitizers for radiotherapy (RT). These NDDSs can release loaded agents at a right dose in the right place at the right time, resulting in greater effectiveness and lower toxicity. Immunotherapeutic agents can also be combined with these NDDSs to achieve the synergic antitumor effect in a multi‐modality therapeutic approach. In this review, NDDSs are harnessed to load multiple agents to induce ICD by chemotherapy, PDT, PTT, and RT in combination of immunotherapy to promote the therapeutic effect and reduce side effects associated with cancer treatment.

show abstract

Section: Design Of Nddss To Deliver Icd‐based Therapeutic Agentsmentioning

confidence: 99%

Section: Icd Induced By Nddss In Combination With Immunotherapymentioning

confidence: 99%

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…MDSCs mainly accumulate in peripheral lymphoid organs and tumor tissues, and promote tumor occurrence, development, and metastasis through releasing IL-10, IDO, Arginase-1 (Arg-1), activating Tregs, inhibiting the functions of T cells and NK cells . Thus, the anti-tumor immune response can be restored by blocking, reprogramming, or depleting MDSCs …”

Section: Tumor Immune Escape: Nanoparticle-based Strategies For Remod...mentioning

confidence: 98%

“…179 Thus, the anti-tumor immune response can be restored by blocking, reprogramming, or depleting MDSCs. 180 In Sasso et al's recent study, a PEGylated lipid nanocapsule loading lauroyl-modified gemcitabine was developed to enhance the therapeutic efficacy by reducing the percentage of spleen and tumor-infiltrating MDSCs in both melanoma and lymphoma models. 181 However, the elimination of MDSCs usually leads to serious adverse effects, so inhibiting the expansion and tumor trafficking of MDSCs may be a safe and effective method for cancer treatment.…”

Section: Tumor Immune Escape: Nanoparticle-based Strategies For Remod...mentioning

confidence: 99%

Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Immunotherapy that harnesses the human immune system to fight cancer has received widespread attention and become a mainstream strategy for cancer treatment. Cancer immunotherapy not only eliminates primary tumors but also treats metastasis and recurrence, representing a major advantage over traditional cancer treatments. Recently with the development of nanotechnology, there exists much work applying nanomaterials to cancer immunotherapy on the basis of their excellent physiochemical properties, such as efficient tissue-specific delivery function, huge specific surface area, and controllable surface chemistry. Consequently, nanotechnology holds significant potential in improving the efficacy of cancer immunotherapy. Nanotechnology-based immunotherapy mainly manifests its inhibitory effect on tumors via two different approaches: one is to produce an effective anti-tumor immune response during tumorigenesis, and the other is to enhance tumor immune defense ability by modulating the immune suppression mechanism in the tumor microenvironment. With the success of tumor immunotherapy, understanding the interaction between the immune system and smart nanomedicine has provided vigorous vitality for the development of cancer treatment. This review highlights the application, progress, and prospect of nanomedicine in the process of tumor immunoediting and also discusses several engineering methods to improve the efficiency of tumor treatment.

show abstract

“…Instead, abnormal metabolism induced specific tumor microenvironments (TMEs) have been closely associated with colorectal cancer metastasis. , Effective prevention and treatment of metastases become extremely important to improve patient survival. In the past decade, photodynamic therapy (PDT) has received increasing attention for tumor treatment owing to its unique superiority such as minimal invasiveness, low side effects, and on-demand light controllability. − Importantly, PDT could induce an immunogenic cell death (ICD) of tumor cells to activate the cascade immune response. − Nevertheless, PDT could inadequately activate antitumor immunity due to immunosuppressive TMEs. − Therefore, an amplified immunotherapy is urgently needed to complement PDT for simultaneous inhibition of tumor growth and metastasis by TME reprogramming.…”

mentioning

confidence: 99%

Self-Delivery Ternary Bioregulators for Photodynamic Amplified Immunotherapy by Tumor Microenvironment Reprogramming

et al. 2022

View full text Add to dashboard Cite

Abnormal metabolism of cancer cells results in complex tumor microenvironments (TME), which play a dominant role in tumor metastasis. Herein, self-delivery ternary bioregulators (designated as TerBio) are constructed for photodynamic amplified immunotherapy against colorectal cancer by TME reprogramming. Specifically, carrier-free TerBio are prepared by the self-assembly of chlorine e6, SB505124 (SB), and lonidamine (Lon), which exhibit improved tumor accumulation, tumor penetration, and cellular uptake behaviors. Interestingly, TerBio-mediated photodynamic therapy (PDT) could not only inhibit the primary tumor growth but also induce immunogenic cell death of tumors to activate the cascade immune response. Furthermore, TerBio are capable of TME reprograming by SB-triggered transforming growth factor (TGF)-β blockage and Lon-induced lactic acid efflux inhibition. As a consequence, TerBio significantly suppresses distant and metastatic tumor growth by PDT-amplified immunotherapy. This study might advance the development of self-delivery nanomedicine against malignant tumor growth and metastasis.

show abstract

Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

Cited by 20 publications

References 213 publications

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment

Self-Delivery Ternary Bioregulators for Photodynamic Amplified Immunotherapy by Tumor Microenvironment Reprogramming

Contact Info

Product

Resources

About